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h i g h l i g h t s
16
17  Quinoline derivatives are effective at
18 inhibiting the growth of Toxoplasma.
19  Some quinolones cause the
20 disappearance of the apicoplast.
21  8-Hydroxyquinoline is very effective
22 to inhibit the growth of Toxoplasma.
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a b s t r a c t
39Here we reported our investigation, as part of our drug repositioning effort, on anti-Toxoplasma properties
40of newly synthesized quinoline compounds. A collection of 4-aminoquinoline and 4-piperazinylquinoline
41analogs have recently been synthesized for use in cancer chemotherapy. Some analogs were able to out-
42perform chloroquine, a quinoline derivative drug which is commonly used in the treatment of malaria
43and other parasitic infections. Herein 58 compounds containing one or two quinoline rings were exam-
44ined for their effectiveness as potential anti-Toxoplasma compounds. Of these 58 compounds, 32 were
45efﬁcient at inhibiting Toxoplasma growth (IC50 < 100 lM). Five compounds with single and simple quin-
46oline rings exhibited similar cLogP values of 2 and IC50 values between 5 and 6 lM, with one exception
47of 8-hydroxyquinoline whose IC50 value was 213 nM. The addition of one hydroxyl group at position 8
48caused a 40-fold increase in the inhibitory effect of quinoline. A signiﬁcant improvement in anti-Toxo-
49plasma effect among quinoline derivatives was detected in B11, B12, B23, and B24, whose structures
50carry two quinoline rings, and their resultant cLogP values are P7. Among these compounds, B23 was
51the most effective compound with IC50 value of 425 ± 35 nM, and TI value of 4.9. It was also noted that
52compounds with at least one quinoline ring, displaying anti-Toxoplasma effects were capable of causing
53the disappearance of the apicoplast, a plastid-like organelle. When treated with quinoline, 8-hydroxy-
54quinoline or B23, 40–45% of the parasites lost their apicoplasts. Our ﬁndings recapitulate the properties
55of quinoline derivatives in diminishing apicoplast. This could aid further investigations of anti-parasitic
56treatments speciﬁc to Apicomplexan. More importantly, B12 and B23 which harbor superior anti-cancer
57properties than chloroquine, have effective anti-Toxoplasma activity. These compounds therefore have
58signiﬁcant potential for future development of chemotherapeutic agents for patients suffering from
59breast cancers and parasitic infection.
60 2014 Elsevier Inc. All rights reserved.
61
62
63
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64 1. Introduction
65 Quinoline alkaloids, heterocyclic aromatic organic (C9H7N) nat-
66 ural compounds, are known to harbor various medicinal properties
67 and are present in a number of national pharmacopoeias. Their
68 synthetic quinoline counterparts also carry important biological
69 activities. 8-Hydroxyquinoline has growth inhibitory effects
70 against gram positive bacteria and some lower level eukaryotes
71 (Shen et al., 1999), and has been used in the veterinary sciences
72 as an antimicrobial agent for topical treatment (Gershon et al.,
73 1985). The mode of action of 8-hydroxyquinoline is a result of its
74 chemical property as a metal chelator and thought to sequester
75 metals necessary for important enzymes in micro-organisms
76 (Shen et al., 1999). 8-Nitroquinoline has been successfully
77 exploited in the treatment of topical pathogenic parasitic Leish-
78 mania infection (Paloque et al., 2012). As early as the 17th century,
79 quinine [(R)-(6-Methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinucli-
80 din-2-yl)methanol], an active constituent from the barks of cin-
81 chona tree, was used both as a muscle relaxant to halt shivering
82 due to the infection caused by Plasmodium spp. and as an anti-
83 malaria agent. Malaria was and remains a serious and sometimes
84 fatal disease. Due to an overwhelming demand for quinine and
85 limited supplies of cinchona barks, the need for readily available
86 and alternative sources of quinine-equivalent compounds gave rise
87 to the discovery of the ﬁrst synthetic acridine derivative, quina-
88 crine [(RS)-N0-(6-chloro-2-methoxy-acridin-9-yl)-N,N-diethyl-pen-
89 tane-1,4-diamine], around the time of the First World War (Butler
90 et al., 2010). Soon after the discovery of quinacrine, a more potent
91 quinoline derivative, chloroquine [(RS)-N0-(7-chloroquinolin-4-yl)-
92 N,N-diethyl-pentane-1,4-diamine], was synthesized (Butler et al.,
93 2010; Solomon et al., 2009). Quinine, quinacrine, and chloroquine
94 are still currently used as anti-malaria agents (Butler et al.,
95 2010). It was hypothesize that these compounds prevent the for-
96 mation of hemozoin by Plasmodium parasites (Foley and Tilley,
97 1998). Hemozoin detoxiﬁes free heme intracellularly, as free heme
98 and heme-drug complexes destroy the parasite by creating oxida-
99 tive stress (Slater, 1992). More detailed structural and functional
100 studies showed that 7-halo substituted compounds are the most
101 active compound. Chloroquine, a 4-aminoquinoline carrying a
102 chlorine moiety at position 7, is an effective anti-malaria agent cur-
103 rently used in the treatment and prevention of malaria (Butler
104 et al., 2010), and as a reference compound to evaluate the ability
105 of chemicals to inhibit hemozoin formation (Foley and Tilley,
106 1998). Despite their effectiveness, emerging resistance of Plasmo-
107 dium spp. has stimulated further drug discovery and development
108 (Butler et al., 2010).
109 A simple backbone quinoline and 2-methyl-3-carbethoxyquino-
110 line have also been shown to inhibit the growth of Toxoplasma
111 gondii, a Plasmodium-related parasite. When treated with either
112 simple quinoline or 2-methyl-3-carbethoxyquinoline, 52–57% of
113 Toxoplasma lost their unique organelle called apicoplast (Smith
114 et al., 2007). Similar activity was previously reported with cipro-
115 ﬂoxacin, a ﬂuoroquinolone derivative (Fichera and Roos, 1997). It
116 was hypothesized that the crucial pharmacophore conferring this
117 biological activity is the quinoline ring structure (Smith et al.,
118 2007). Interestingly, the presence of an apicoplast is generally used
119 in grouping Plasmodium and Toxoplasma parasites as pathogenic
120 members of the Apicomplexa phylum. The apicoplast is a non-pho-
121 tosynthetic plastid organelle. In Plasmodium and Toxoplasma para-
122 sites, the apicoplast is crucial for three essential metabolic
123 functions: the synthesis of heme, type II fatty acids and isoprenoid
124 precursors (Sheiner et al., 2013), and thus has long been considered
125 an ideal target for treating infection caused by Apicomplexan
126 (Fichera and Roos, 1997). Pathogenic Apicomplexan, besides Plas-
127 modium (malaria in humans) and Toxoplasma (toxoplasmosis in
128humans and animals), are the following. Cryptosporidium can cause
129cryptosporidiosis whose major symptom in humans is diarrhea
130(Tzipori and Ward, 2002). Eimeria is the major cause of coccidiosis
131in agriculturally important animals, including poultry, sheep, and
132cattle (Shirley and Harvey, 2000). Babesia parasites can cause a
133hemolytic disease known as babesiosis in humans and occasionally
134in domestic animals (Vannier and Krause, 2009). Neospora is an
135important protozoan pathogen in cattle and dogs, while Theileria
136are important cattle parasites (Katzer et al., 2011).
137Drug repositioning can be described as the investigation of new
138medicinal uses and purposes for previously known and tested drugs
139(Solomon et al., 2010a, 2010b). Such practices could help overcome
140high costs and time often associated with the development of new
141drugs because the known and tested drugs have previously or gen-
142erally been evaluated or recognized for their pharmacokinetics
143properties (Chong and Sullivan, 2007). The repositioning studies
144of chloroquine derivatives (Solomon et al., 2010a, 2010b) have
145been very valuable in generating a large collection of quinoline
146derivatives. By combining two important pharmacophores, 4-
147piperazinylquinolones and isatin structure, novel compounds were
148created with versatile biological effects. For example, B12 and B23
149with their hybrid pharmacophore exhibit cancer-speciﬁc and are
150more effective than chloroquine (Solomon et al., 2010b). Due to
151the presence of multiple structural determinants of the hybrid
152pharmacophores, these newly generated compounds harbor great
153potentials to target different sites or molecules, which might result
154in the possibility to disrupt multiple cellular mechanisms simulta-
155neously and/or to overcome drug resistance (Meunier, 2007).
156Here we reported our evaluation for anti-Toxoplasma activity of
157a wide array of quinoline derivatives, ranging from simple mole-
158cules with null or one substitution to multiple substitutions
159(Tables 1–3). Toxoplasma was chosen as our model organism
160because (1) it can be easily cultivated in vitro using human ﬁbro-
161blast monolayers (HFF); (2) its doubling time is relatively short
162(7 h) (Seeber and Boothroyd, 1996); (3) the availability of its 2F
163strain to express beta-galactosidase reporter system offers an accu-
164rate and effective growth evaluation (Seeber and Boothroyd, 1996),
165and (4) protocols for growth inhibition and toxicity assays are well
166documented (Seeber and Boothroyd, 1996; Jones-Brando et al.,
1672003). In general, Toxoplasma infection is quite common, affecting
168a quarter of the world’s population, although not all infections lead
169to lethal toxoplasmosis. Toxoplasma infection can cause very mild
170or no symptom in healthy individuals, but becomes severe in
171immunocompromised individuals (Montoya and Rosso, 2005).
172The infection occurs via ingestion of contaminated food or water.
173If the infection takes place during pregnancy, the parasite could
174be transmitted to a fetus and could cause blindness and mental
175retardation. Current treatments for Toxoplasma infection include
176pyrimethamine in combination with sulfadiazine and/or clindamy-
177cin (Montoya and Rosso, 2005). Pyrimethamine and sulfadiazine
178inhibit the enzyme dihydrofolate reductase of the tetrahydrofolic
179acid synthesis, whereas clindamycin inhibits bacterial protein syn-
180thesis by inhibiting ribosomal translocation. These current treat-
181ments could have severe side effects such as, the inhibition of
182bone marrow formation and the teratogenic nature of pyrimeth-
183amine as a folate inhibitor, precluding it from being used in preg-
184nant women during their ﬁrst trimester. Sulfadiazine could cause
185allergic reactions in immunocompromised individuals (Montoya
186and Rosso, 2005; Peters et al., 2007). Because of these limitations
187associated with current treatments, it is of great importance to
188evaluate and ﬁnd alternative safe treatments. Evaluation of the
189biological properties of quinoline compounds for their ability to
190inhibit the growth of Toxoplasma could reap beneﬁts for the ongo-
191ing search for effective treatments against the devastating effects
192of apicomplexan infection.
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193 2. Materials and methods
194 2.1. Chemicals
195 Compounds in Table 1 were obtained from Sigma-Aldrich (Can-
196 ada), while others in Tables 2 and 3 were synthesized and puriﬁed
197 according to Solomon et al. (2010a, 2010b). Stock solutions
198 (10 mM) were prepared in DMSO or water, kept at 20 C and
199 diluted to desirable concentrations when needed.
200 2.2. Cell and parasite cultures
201 HFFs were grown into conﬂuent monolayers for cytotoxicity
202 and parasite’s growth inhibition assays using DMEM (Invitrogen,
203 Canada) which was supplemented with 10% cosmic calf serum
204 (Hyclone, Utah), and 0.5x Antibiotic-Antimycotic (Invitrogen, Can-
205 ada). Toxoplasma strain 2F was obtained from ATCC and prolifer-
206 ated using HFF in MEM containing L-glutamine (Invitrogen,
207 Canada) which was supplemented with 1% dialyzed fetal bovine
208 serum and 0.5x Antibiotic-Antimycotic and 20 lg/mL gentamycin
209 (Gibco, Canada).
210 2.3. Parasite growth inhibition and cytotoxicity assays
211 Protocols described by McFadden et al. (1997) and
212 Jones-Brando et al. (2003) were adapted for our study. Brieﬂy
213HFF monolayers were grown in 96-well plates and used for evalu-
214ation of cellular cytotoxicity of the compounds and their ability to
215inhibit the growth of Toxoplasma. Immediately prior to the evalua-
216tions, their regular culturing media were rinsed twice and replaced
217with 150 ll culturing media [1% dialyzed fetal bovine serum
218(Hyclone, Logan, Utah), and 0.5% Antibiotic-Antimycotic supple-
219mented MEM lacking phenol red, cat #M3024-10X1L, Sigma–
220Aldrich, Canada)]. Tested compounds were added and serially
221diluted into 11 columns of the plates. Generally the compounds
222were diluted to achieve concentrations ranging from 10 lM to
2230.01 lM. However, for some compounds a higher range (100 lM
224to 0.1 lM) was needed. Into the six rows (6/8) of the plates,
225approximately 50 tachyzoites of 2F parasites were added and incu-
226bated for 4 days at 37 C and 5% CO2. On day 4, chlorophenol Red-
227b-D–galactoside (CPRG, Sigma-Aldrich, Canada) was added to the
228wells containing infected monolayers to a ﬁnal concentration of
229100 lM. On the following day, into two (2/8) rows without the par-
230asite additions, cytotoxicity testing reagent called MTT (3-[4, 5-
231dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) (Sigma,
232Canada) was added to a ﬁnal concentration of 5 mg/ml. The plates
233were incubated for 4 h to allow for tetrazolium salt to form as an
234indicator of mitochondrial function (Mosmann, 1983). Q2The culture
235media in the row containing MTT solution was replaced with
236100 ll of N-N-dimethylformamide containing 5% SDS. The prod-
237ucts of beta-galactosidase and cytotoxicity assays were purple
238allowing the absorbance measurement at 560 nM using a Victor3
Table 1
Simple quinolines.
Compound name Structure cLogP IC50 (lM) TD50 (lM) TI
Quinoline
6
7
8
5
2
3
4
N
1
2.03 8.00 ± 2.83 12.5 ± 0.707 1.56
8-Hydroxyquinoline
N
1
2
3
45
6
7
8
OH
2.08 0.213 ± 0.194 0.500 ± 0.0707 2.35
2-Chloroquinoline
6
7
8
5
2
3
4
N
1
Cl
2.83 5.75 ± 1.06 8.50 ± 2.12 1.48
5-Nitroquinoline
N
1
2
3
45
6
7
8
NO2 1.91 7.25 ± 0.354 11.3 ± 2.47 1.56
Quinoline N-oxide hydrate
N1
2
3
45
6
7
8
O-
H2O 1.42 6.40 ± 2.26 7.50 ± 2.12 1.17
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239 microplate reader (Perkin Elmer Life and Analytical Sciences,
240 Woodbridge, ON, Canada). The median inhibitory and cytotoxic
241 doses were used for the calculation, where experimental data were
242 not constrained to 0% and 100%. The Reed–Muench formula (Reed
243 and Muench, 1938) was applied to obtain the concentration at
244 which 50% of parasite multiplication (IC50) was effectively inhib-
245 ited, and the concentration at which 50% of the monolayers exhib-
246 ited cytotoxic effect (TD50). Therapeutic index (TI) was calculated
247 as TI = TD50/IC50.
248 2.4. Microscopic determination
249 HFFs were grown on coverslips and infected with 2F for 24 h.
250 The media was replaced with chilled methanol for ﬁxing. Hoechst
251 solution (10 lM) was used to stain DNA containing organelles to
252 allow for microscopic determination of apicoplasts. For each test,
253at least 50 independent ﬁelds of view were examined for whether
254or not the parasites had retained their apicoplasts (Leica ﬂuores-
255cence microscope). Average percentage of the numbers of the par-
256asites with apicoplasts was calculated from each test and for each
257compound. Three experimental replicates were performed, from
258which a ﬁnal average for each compound was obtained. A one-
259way ANOVA with corrections for multiple comparisons using the
260Bonferroni method was performed, with alpha set as 0.05/5 to
261account for different treatment groups (McDonald, 2008). Further-
262more, a two tailed student’s t-test was performed to test the null
263hypothesis, that there was no statistical difference between the
264treatment of parasites with DMSO and the tested compounds.
265The value of alpha, which is associated with the conﬁdence level
266of the experiments, was set at 0.05 (1–0.95) for results with 95%
267level of conﬁdence. The results were tabulated and used in com-
268paring the effects among the treatments.
Table 2
4-Piperazinylquinoline derived compounds.
Compound name Structure X R cLogP IC50 (lM) TD50 (lM) TI
A2
6
7
8
5
2
3
4
N
1
N
N
X
N
O
O
R
Cl 4-Br 5.03 4.25 ± 0.353 9.97 ± 2.05 2.35
A3 Cl 6-Cl 4.95 2.40 ± 1.41 11.7 ± 2.88 4.88
A4 Cl 6-Br 5.03 3.50 ± 1.414 9.50 ± 0.707 2.71
A5 Cl H 3.99 2.75 ± 0.354 8.00 ± 0.707 2.91
A6 CF3 4-Cl 5.10 4.00 ± 2.83 7.95 ± 0.070 1.99
A7 CF3 4-Br 5.25 7.5 ± 2.12 14.0 ± 1.41 1.87
A11
6
7
8
5
2
3
4
N
1
N
N
X
N
O
N
R
H
N
S
NH2
Cl 4-Cl 5.18 0.895 ± 0.418 5.00 ± 0.707 5.59
A12 Cl 4-Br 5.33 2.45 ± 0.777 8.00 ± 1.41 3.27
A14 Cl 6-Br 5.33 0.800 ± 0.282 2.80 ± 0.283 3.50
A15 CF3 4-Cl 5.40 2.10 ± 0.141 8.00 ± 1.414 3.81
A16 CF3 4-Br 5.55 1.75 ± 0.354 5.75 ± 0.353 3.29
A17 CF3 6-Cl 5.40 1.05 ± 0.354 4.75 ± 0.354 4.52
A18 CF3 6-Br 5.55 0.725 ± 0.176 3.15 ± 0.495 4.34
A24
N
H
O
NHN
S
H2N
R
– H 1.26 3.00 ± 0.707 9.00 ± 1.41 3.00
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269 3. Results and discussion
270 3.1. Toxoplasma growth inhibition and cytotoxicity
271 Fifty-eight compounds were divided into three groups; (i) ﬁve
272 quinolines with single substituents, (ii) twenty-four analogs of
273 4-piperazinylquinoline (group A), and (iii) twenty-nine 4-amino-
274 quinoline derivatives (groups B), for which chloroquine was used
275as reference compound. Notably, DMSO at tested concentrations
276yielded no adverse effect to HFF and 2F. From the initial round of
277evaluation, eighteen compounds which did not exhibit a growth
278inhibition curve were eliminated from the list. Among the remain-
279ing forty compounds, eight compounds, which exhibited IC50 >
280100 lM, were deemed less probable for further testing due to their
281limited potency. The remaining thirty-two compounds were
282subjected to at least two independent assays of which each assay
Table 3
Chloroquine derived compounds.
Compound number Structure cLogP IC50(lM) TD50(lM) TI
Chloroquine
6
7
8
5
2
3
4
N
1
HN
Cl
N
5.06 2.25 ± 0.354 9.00 ± 1.41 4.00
B4
6
7
8
5
2
3
4
N
1
HN O
F3C
S
O
O
CH3
3.54 1.35 ± 0.212 5.67 ± 1.15 4.20
B11
6
7
8
5
2
3
4
N
1
HN
Cl
N
N
N
Cl 7.00 0.875 ± 0.177 1.43 ± 0.513 1.63
B12
6
7
8
5
2
3
4
N
1
HN
Cl
N
N
N
CF3 7.13 0.750 ± 0.141 1.27 ± 0.550 1.69
B15
6
7
8
5
2
3
4
N
1
HN N
Cl
O
O
Cl 5.06 0.95 ± 0.071 5.25 ± 0.354 5.53
(continued on next page)
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Table 3 (continued)
Compound number Structure cLogP IC50(lM) TD50(lM) TI
B16
6
7
8
5
2
3
4
N
1
HN N
Cl
O
O
Br 5.21 1.13 ± 0.671 3.75 ± 0.354 3.32
B18
6
7
8
5
2
3
4
N
1
HN
F3C
N
4.70 5.25 ± 0.354 10.0 ± 1.41 1.90
B22
6
7
8
5
2
3
4
N
1
HN
F3C
N
N
6.03 1.13 ± 0.247 3.00 ± 1.41 2.65
B23
6
7
8
5
2
3
4
N
1
HN
F3C
N
N
N
Cl 7.25 0.425 ± 0.035 2.1 ± 0.566 4.94
B24
6
7
8
5
2
3
4
N
1
HN
F3C
N
N
N
CF3 7.46 0.450 ± 0.071 1.75 ± 0.354 3.89
B26
6
7
8
5
2
3
4
N
1
HN N
F3C
O
O
Cl
5.30 4.75 ± 1.06 8.25 ± 1.77 1.74
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283 generated at least 8 data points for each test. Their IC50 and
284 TD50 were calculated and analyzed in comparison to their cLogP
285 values.
286 Simple quinolines (Table 1) were tested to verify the hypothesis
287 made by Smith et al. (2007) that the quinoline rings is the active
288 moiety causing growth inhibition. All compounds of this group dis-
289 played IC50 at <10 lM. Quinoline and 5-nitroquinoline, have cLogP
290 values; 2.03 and 1.91 respectively. The values of cLogP are com-
291 monly used to correlate the ability of a compound to cross the cell
292 membranes; a low value indicates that the compound is relatively
293 hydrophilic and less likely to cross the cell membrane. Both com-
294 pounds have similar cLogP values, which could explain the similar-
295 ities in their IC50 values at 8.00 ± 2.83 lM and 7.25 ± 0.354 lM, and
296 their TD50 values at 12.5 ± 0.707 lM and 11.3 ± 2.47 lM, respec-
297 tively. This suggested that that the 5-nitro substitution did not
298 have a signiﬁcant effect. 2-Chloroquinoline has a slightly higher
299 cLogP value of 2.83, while showing the IC50 value of
300 5.75 ± 1.06 lM and TD50 of 8.50 ± 2.12 lM. Within this group,
301 quinoline-N-oxide hydrate has the lowest cLogP value at 1.42,
302 with the IC50 of 6.40 ± 2.26 lM and TD50 of 7.50 ± 2.12 lM, giving
303 this compound the lowest therapeutic index among the series.
304 Interestingly, 8-hydroxyquinoline, with a cLogP value 2.08, which
305 is close to those of quinoline and 5-nitroquinoline, displayed IC50
306 of 0.213 ± 0.194 lM and TD50 of 0.500 ± 0.0707 lM, resulted in
307 more than a 2-fold difference in both IC50 and TD50, when com-
308 pared to the other compounds displaying similar cLogP values. This
309 thus indicated that the 8-subsition of a quinoline ring has the
310 strongest inﬂuence on the tested activities. It was not surprising
311 because 8-hydroxyquinoline is known to have antiseptic and anti-
312 fungal properties against gram positive bacteria (Shen et al., 1999)
313 and used as a topical treatment for skin infections (Gershon et al.,
314 1985). Studies in Plasmodium spp. (Scheibel and Adler, 1982)
315 showed that 8-hydroquinoline could act as a chelating agent, and
316 in Cryptosporidium parvum and related species including T. gondii
317 (Bessoff et al., 2014) also suggested promising uses of 8-hydro-
318 quinoline and related quinoline derivatives as anti-parasitic
319 agents. It should be noted that despite a low cLogP value (2), 8-
320 hydroxyquinoline is the most effective, suggesting that it might
321be up taken by other means than passively traversing the cell
322membranes.
323Compounds of group A (Table 2) were derived from a 4-piperaz-
324inylquinoline backbone. These compounds are an example of
325hybrid pharmacophores, including an isatin ring, a quinoline ring
326and/or a thiosemcarbazone moiety. These moieties have been
327reported as important pharmacophores conferring various biolog-
328ical actions and effectiveness in the treatment of cancer
329(Brockman et al., 1956; Solomon et al., 2009; Hu et al., 2010).
330The compounds were here presented and compared based on their
331substituents to the 4-piperazinylquinoline ring system and the
332nature of the group on the 7-position of the 4-piperazinylquinoline
333ring. In order to evaluate which of the moieties within these hybrid
334pharmacophores was eliciting the highest bioactivity, a group of
335thiosemicarbazone derived compounds with isatin ring systems
336and not containing a quinoline ring system were tested. The isatin
337rings were either chloro substituted (A20, A22), bromo substituted
338(A21, A23), or non-substituted (A24). Of these ﬁve compounds,
339only A24 proved to elicit inhibitory effects with an IC50 of
3403.00 ± 0.707 lM and a TD50 of 9.00 ± 1.41 lM. This compound does
341not contain a quinoline ring and displays an inhibition effect sug-
342gesting that the isatin ring system or the thiosemicarbazone, are
343as active as suggested by (Krivogorsky et al., 2008; Tenório et al.,
3442005). Compared to simple quinolines described earlier, this group
345was less effective and showed less potential in Toxoplasma
346inhibition.
347A2–A5 are derived from a 7-chloro-4-piperazinylquinoline ring
348system with a substituted isatin ring substituted with a 4-bromo
349(A2), a 6-chloro (A3), a 6-bromo (A4), or a non-substituted isatin
350ring (A5). All of these compounds proved to have similar abilities
351at inhibiting Toxoplasma, with the exception of A3, with an IC50 of
3522.40 ± 1.41 lM and a TD50 of 11.7 ± 2.88 lM. Interestingly, A3 had
353a similar cLogP value to A2 (IC50 = 4.25 ± 0.353 lM, TD50 = 9.97 ±
3542.05 lM), and A4 (IC50 = 3.50 ± 1.41 lM, TD50 = 9.50 ± 0.707 lM).
355A5, which displayed the lowest cLogP value among the 4 com-
356pounds, inhibited the growth of Toxoplasma with an IC50 of 2.75 ±
3570.354 lM and a TD50 of 8.00 ± 0.707 lM, and was comparable in
358activity to A4. A6, A7 were derived from a 7-triﬂuoromethyl-4-
Table 3 (continued)
Compound number Structure cLogP IC50(lM) TD50(lM) TI
B27
6
7
8
5
2
3
4
N
1
HN N
F3C
O
O
Br
5.45 2.00 ± 0.01 11.0 ± 1.41 5.50
B29
6
7
8
5
2
3
4
N
1
HN N
F3C
O
O
Br 5.45 1.20 ± 1.13 4.75 ± 0.354 3.96
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359 piperazinyl ring system substituted with a 4-chloro (A6), 4-bromo
360 (A7) isatin ring. A6 displayed an IC50 value of 4.00 ± 2.83 lM and a
361 TD50 value of 7.95 ± 0.07 lM. Within this group, A7 had relatively
362 high TD50 of 14.0 ± 1.41 lMand IC50 of 7.5 ± 2.12 lM. The twobiois-
363 oteric groups, with their main chains differing only by the group
364 substituted on the 7-position of the 4-piperazinylquinoline lateral
365 side chain (either CF3 or Cl group), generally, did not differ much
366 in their biological effects, with the exception of A3 displaying the
367 greatest TI.
368 The next analyses were carried out for those compounds which
369 were derived from a 7-chlorosubstituted 4-piperazinylquinoline
370 ring system attached to a substituted isatin-3-thiosemicarbazone
371 ring system to carry either a 4-chloro (A11), 4-bromo (A12), or a
372 6-bromo (A14) substitution. Among these three compounds, A11
373 proved to be the most effective displaying an IC50 of 0.895 ±
374 0.418 lM and a TD50 of 5.00 ± 0.707 lM, with A14 just behind it
375 in terms of effectiveness, the IC50 value of A14 was 0.800 ±
376 0.282 lM and its TD50 value was 2.80 ± 0.283 lM, making A14
377 slightly more cytotoxic to HFF than A11. Of the three compounds,
378 A12 proved to be the least effective with an IC50 of 2.45 ± 0.777 lM
379 and a TD50 value of 8.00 ± 1.41 lM. Their bioisoteric counterparts,
380 which contained a 7-triﬂuoromethyl-4-piperazinylquinoline ring
381 system attached a substituted isatin-3-thiosemicarbazone ring
382 system with either a 4-chloro (A15), 4-bromo (A16), 6-chloro
383 (A17), or 6-bromo (A18) group, were generally similar in their abil-
384 ity to inhibit Toxoplasma, with A15 displaying an IC50 value
385 2.10 ± 0.141 lM and a TD50 of 8.00 ± 1.41 lM, A16 with an IC50
386 value of 1.75 ± 0.354 lM and a TD50 value of 5.75 ± 0.353 lM, with
387 A17 displaying an IC50 value of 1.05 ± 0.354 lM and a TD50 of
388 4.75 ± 0.354 lM, and A18 displaying an IC50 value of 0.725 ±
389 0.176 lM, and a TD50 of 3.15 ± 0.495 lM. When comparing the
390 two bioisoteric groups, 7-chloro vs. 7-triﬂuoromethyl on the 4-pip-
391 erazinyl quinoline ring, those with the 7-chloro group proved to be
392 slightly more effective. Noted, compounds with a chloro substi-
393 tuted isatin ring were generally the most effective compounds dis-
394 playing the greatest TI. Taken together, compounds containing the
395 thiosemicarbazone moiety attached to the isatin ring were gener-
396 ally more effective than the compounds containing simply an isat-
397 in ring. This could be due the ability of quinoline, isatin, and
398 thiosemicarbazone to inhibit Toxoplasma independently. Additive
399 inhibitory effects on Toxoplasma could result in a more potent
400 pharmacophore. This is similar to the effects observed by
401 Solomon et al. (2010a).
402 The ﬁnal set of 29 compounds (group B) was derived from a 4-
403 amino quinoline backbone of chloroquine. As a benchmark com-
404 pound for comparison, chloroquine has a cLogP value of 5.06,
405 IC50 of 2.25 ± 0.354 lM and TD50 of 9.00 ± 1.41 lM. Only twelve
406 compounds of this set showed inhibitory effects (Table 3) and were
407 compared based on their substituent attached to the 4-aminoquin-
408 oline ring system and the nature of the group on the 7-position of
409 the 4-aminoquinoline ring. B11 and B12 were derived from a
410 7-chloro-4-aminoquinoline side chain substituted with a 4-quin-
411 olinyl-piperazinyl chain. B11 has a 4-(7-Chloroquinolin-4-yl)pip-
412 erazin-1-yl group attached the lateral side chain, while B12 has a
413 4-(7-triﬂuoromethylquinolin-4-yl)piperazin-1-yl attached to the
414 lateral side chain, giving these two compounds differ only by one
415 substitution either a CF3 or a Cl at the 7-position of the 4-quinoli-
416 nyl-piperazinyl chain. Both do not differ signiﬁcantly with the IC50
417 values of 0.875 ± 0.177 lM and 0.750 ± 0.141 lM, and their TD50
418 values of 1.43 ± 0.513 lM and 1.27 ± 0.550 lM, with their cLogP
419 values at 7.00 and 7.13 for B11 and B12, respectively. Correspond-
420 ingly B23 and B24were derived from the bioisoteric substitution of
421 the 7-chloro group with a 7-triﬂuoromethyl group on the 4-amino-
422 quinoline ring, with B23 being the bioisoteric counterpart of B11,
423 and B24 of B12. When compared to one another, the activities dis-
424played by B23 and B24 did not differ signiﬁcantly in their activi-
425ties: B23 with an IC50 of 0.425 ± 0.035 lM and TD50 of
4262.10 ± 0.566 lM, and B24 with an IC50 of 0.450 ± 0.071 lM and a
427TD50 of 1.75 ± 0.0.354 lM. Also, their cLogP values were similar;
428B23, 7.25, and B24, 7.46. When compared to their bioisoteric coun-
429terparts, no signiﬁcant difference was observed, however B23 and
430B24 were active at slightly lower concentrations, which could be
431due to their greater cLogP values. A substitution of a 4-(7-triﬂuo-
432romethylquinolin-4-yl)piperazin-1-yl ring system on a 4-amino-
433quinoline lateral side chain proved to be more effective when
434there is a CF3 group at the seventh position of the ring, but not sig-
435niﬁcantly so, as evidenced by the IC50 values of B23 and B24 vs.
436those of B11 and B12. Notably, the nature of the substituent at
437the 7-position of the ring, either Cl or CF3 does not seem to have
438a signiﬁcant effect on the parasitic growth inhibition. This is differ-
439ent from what was observed in the proliferation of cancer cells,
440where a Cl group substitution at the seventh position of the ring
441was the more effective agent at inhibiting cancer cell proliferation.
442B15 and B16 contain a halogenated isatin ring system on a
4437-chloro-4-aminoquinoline lateral side chain. B15 containing a
4446-chloroisatin ring, and B16 a 6-bromoisatin ring. In terms of the
445inhibitory activity, there was no signiﬁcant difference. B15 with
446an IC50 0.950 ± 0.071 lM and a TD50 of 5.25 ± 0.354 lM, while
447B16 had an IC50 1.13 ± 0.671 lM and TD50 of 3.75 ± 0.354 lM.
448When B26, B27, and B29, derived from a bioisoteric replacement
449of the 7-chloro group with a 7-triﬂuoromethyl group on the 4-ami-
450noquinoline ring, were compared, B26 displayed an IC50 of 4.75 ±
4511.06 lM and a TD50 8.25 ± 1.77 lM; B27 an IC50 of 2.00 ± 0.01 lM
452and a TD50 of 11.0 ± 1.41 lM, and B29 an IC50 of 1.20 ± 1.13 lM
453and a TD50 4.75 ± 0.354 lM. The difference in the identity of the
454group on the isatin substituent, B26 with a 4-Cl, B27 with a 4-Br,
455and B29 with a 6-Br group yielded slightly different cLogP values:
4565.30 for B26, 5.45 for both B27 and B29. Interestingly B27 proved
457to be more potent and displayed a TI at least two times greater
458than that of B26 and slightly greater than that of B29.
459It should be noted that the compounds containing substituted
460quinolin-4-yl-4-piperazinyl chains on a 4-aminoquinoline side
461chain (B11, B12, B23, B24) were more effective in inhibiting Toxo-
462plasma than the compounds containing halo-substituted isatin
463rings attached to a 4-aminoquinoline lateral side chain (B15, B16,
464B26, B27, B29). The former group has cLogP values ranging from
4657.00 to 7.46, whereas the latter has cLogP values ranging from
4665.06 to 5.45. The former group contains two quinoline rings, which
467may have an additive effect in terms of causing inhibition as
468opposed to a hybrid pharmacophore containing a quinoline and
469an isatin ring, perhaps further hinting to the potency and efﬁciency
470of the quinoline moiety against the growth of Toxoplasma. B4, con-
471taining a 7-triﬂuoromethylaminoquinoline lateral side chain with
472a methanesulfonate substitution, was more effective than chloro-
473quine with an IC50 value of 1.35 ± 0.212 lM, and a TD50 value of
4745.67 ± 1.15 lM. When compared to the other compounds, which
475contain at least two ring systems, it was comparable to those
476compounds containing an isatin ring system substituted on
4777-chloro-4-aminoquinoline lateral side chain (B15, B16). The cLogP
478value of B4 which is 3.54, this is approximately half of the cLogP
479values observed in B15 and B16.
480When B18, and B22, derived from the 7-triﬂuoromethylamino-
481quinoline lateral side chain, were compared for B18 with a pyrro-
482lidinyl group vs. B22 with a phenylpiperazinyl ring substitution.
483B18 had a relatively high IC50 and TD50 and proved to be less effec-
484tive than chloroquine. Among chloroquine-derived compounds,
485B4, B15, B23, and B27 displayed TI values greater than that of chlo-
486roquine. B23was the most potent of this group displaying the low-
487est IC50 value. Interestingly, B23 was also reported by Solomon
488et al. (2010a) to be more potent than chloroquine as a cancer
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489 chemotherapeutic agent. This indicates that this compound may
490 have the potential to be used for multiple purposes. Surprisingly,
491 the most potent compound proved to be 8-hydroxyquinoline
492 among all compounds tested. 4-Aminoquinoline analogs were
493 slightly more potent than 4-piperazinyl quinoline derivatives, par-
494 ticularly B23 and B24 which displayed IC50 ranging from 425 to
495 585 nM.
496 3.2. Effect on apicoplast
497 Smith et al., (2007) showed that quinoline has an apicoplast-
498 disrupting effect. To evaluate the effect of quinoline derivatives
499 tested here on apicoplast maintenance, quinoline (IC50 8.0 ±
500 2.8 lM), 8-hydroxyquinoline (IC50 213 ± 194 nM), and B23 (IC50
501 425 ± 35 nM) were selected and tested in comparison to B25which
502 was an inactive quinoline derivative with IC50 > 100 lM. To
503 account for various levels of heterogeneity of Toxoplasma cultures,
504 three independent experiments were performed where equal
505 numbers of newly released parasites (1  106 parasites) were
506 used in each experiment. As shown in Fig. 1, due to their growth
507 heterogeneity not all untreated parasites harbored their apicop-
508 lasts (73.2 ± 6.4%). The treatments with quinoline, 8-hydroxyquin-
509 oline, or B23 resulted in the loss of apicoplasts, which can be seen
510 by the smaller proportion of parasites maintaining their apicop-
511 lasts (43.2 ± 3.8%, 43.7 ± 2.8%, and 39.7 ± 4.3%, respectively); these
512 data were accounted for 40–45% loss of apicoplasts, when Toxo-
513 plasma were exposed to the drugs. On the other hand B25 did
514 not cause apicoplast loss, in comparison to untreated parasites
515 (74.9 ± 6.5%). The one-way ANOVA analyses yielded F4,10 = 36.7,
516 P = 5.96  106, and Fcrit was 3.48. Since the F value generated from
517 ANOVA analyses was greater than Fcrit value, it thus indicated sig-
518 niﬁcant differences among tested groups. When the Bonferroni
519 correction was applied, the P values obtained was less than the
520corrected alpha value (0.01), further conﬁrmed the signiﬁcant dif-
521ference among the tested groups. To determine which compounds
522exhibit a statistically signiﬁcant effect on apicoplast disappearance,
523a two tailed student’s t-test was performed, and P values < 0.05
524were obtained. The analysis conﬁrmed the effect of quinoline, 8-
525hydroquinoline and B23 on apicoplast, while B25 showed no effect
526(Fig. 2) Q3.
527Although a precise mechanism of disturbance is unknown, our
528observation is in an agreement with the observations made by
529Smith et al. (2007). The apicoplast disrupting effect detected for
530single and two quinoline ring structures suggested stereo-speciﬁc-
531ity where the single quinoline should be maintained. As seen in the
532structure of inactive B25, the substitutions differing from that of
533another quinoline ring did not elicit any biological effect. Further
534structural elucidation will be required to determine an underlying
535mechanism by which these compounds target the apicoplast bio-
536genesis, and whether they could be further developed for the treat-
537ment of infection caused by apicomplexan. Such an activity was
538not observed, when pyrimethamine or clindamycin was used in
539the treatment of infected monolayers (data not shown). Indirectly,
540it suggested that the effect of quinoline derivatives on apicoplast
541was speciﬁc to the organelle functions, but not due to their general
542toxicity. However, it is remained to be investigated whether and
543how quinoline derivatives could affect metabolic functions of api-
544coplast in the synthesis of heme, type II fatty acids or isoprenoid
545precursors (Sheiner et al., 2013). In conclusion, B23 has the great-
546est effect in causing the disappearance of the apicoplast in compar-
547ison to the other compounds tested and would be the best
548candidate for a future study. Undoubtedly, quinoline compounds
549should be further explored for their effectiveness and selectivity
550as possible anti-parasitic agents for humans as well as animals.
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apicoplasts Standard deviaon p-value
DMSO 73.2 6.4
Quinoline 43.2 3.8 0.005
8-Hydroxyquinoline 43.7 2.8 0.007
B23 39.7 4.3 0.003
B25 74.9 6.5 0.754
Fig. 1. Effects of quinoline derivatives on Toxoplasma. Approximately 1  106
parasites were used to infect conﬂuent HFF monolayers. At the time of infection,
quinoline derivatives were added in the culturing media to obtain the ﬁnal
concentration of 1 or 2 times of IC50, when no cytotoxicity effect was observed. The
ﬁnal concentrations of quinoline were at 8 lM; 8-hydroxyquiniline at 426 nM; B23,
850 nM; B25 0.8–8 lM). Twenty-four hours post infection and drug treatments, the
parasites were examined as described in Materials and Methods. Double daggers ()
indicate P-values < 0.05. Asterisks in the micrograph are for the locations of the
apicoplasts.
Quinoline, cLogP 2.03 
(41%)
8-Hydroxyquinoline, cLogP 2.08
(40%)
B23, cLogP 7.25 (45%)
B25, cLogP 0.82 (0%)
Fig. 2. Structural comparisons. The structures of representative compounds exhib-
iting apicoplast disrupting effects were shown along with their cLogP values and
their effect. In parenthesis, the disruption effect was calculated from the proportion
of parasite without apicoplast in each test group in comparison to those treated
with DMSO solvent.
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